First experience in colorectal surgery with a new robotic platform with haptic feedback

Antonino Spinelli, Giulia David, Stefano Gidaro, Michele Carvello, Matteo Sacchi, Marco Montorsi, Isacco Montroni

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The use of robotic techniques is increasing in colorectal surgery. Recently, the Senhance™surgical robotic system was introduced as a novel robotic platform designed to overcome some of the limits of standard laparoscopy. This study describes the initial, single center experience, evaluating feasibility and safety of the new robotic system in performing colorectal surgical procedures.

METHODS: From June 2015 to November 2016, perioperative data of the first 45 patients who underwent robotic colorectal surgery with the SenhanceTM surgical robotic system were collected and analyzed. Indications for surgery included inflammatory bowel disease, colorectal cancer, endoscopically unresectable adenomas and complicated diverticular disease.

RESULTS: The median age was 57 years (18-92) and the median BMI was 24 Kg/m2 (16-30). Surgical indications were colorectal cancer (66%), complicated inflammatory bowel disease (18%), diverticular disease (11%) and endoscopically unresectable adenoma (4.4%). The median operative time was 256 minutes; the median docking time 10.7 min (range 2-25). There were 3 conversions to standard laparoscopy, and none to laparotomy. All patients operated on for malignancy (28 adenocarcinoma, 2 neuroendocrine tumors) underwent an appropriate oncological procedure. The median time to discharge was 5 days (range 3-19). The incidence of post-operative complications was 35.5% (Clavien-Dindo I/II-14 patients, III-2 patients). One patient was readmitted in the postoperative period. No patient required reoperation.

CONCLUSION: The results of this audit suggest that adoption of The Senhance™surgical robotic system in colorectal surgery is feasible and safe. More clinical data are needed to determine whether this approach can offer any other benefits over other minimally invasive surgical techniques. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalColorectal Disease
DOIs
Publication statusE-pub ahead of print - Sep 14 2017

Fingerprint

Colorectal Surgery
Robotics
Adenoma
Laparoscopy
Colorectal Neoplasms
Neuroendocrine Tumors
Operative Time
Reoperation
Inflammatory Bowel Diseases
Postoperative Period
Laparotomy
Adenocarcinoma
Safety
Incidence

Keywords

  • Journal Article

Cite this

First experience in colorectal surgery with a new robotic platform with haptic feedback. / Spinelli, Antonino; David, Giulia; Gidaro, Stefano; Carvello, Michele; Sacchi, Matteo; Montorsi, Marco; Montroni, Isacco.

In: Colorectal Disease, 14.09.2017.

Research output: Contribution to journalArticle

@article{18c1120578bf4b1c8500adee090576be,
title = "First experience in colorectal surgery with a new robotic platform with haptic feedback",
abstract = "The use of robotic techniques is increasing in colorectal surgery. Recently, the Senhance™surgical robotic system was introduced as a novel robotic platform designed to overcome some of the limits of standard laparoscopy. This study describes the initial, single center experience, evaluating feasibility and safety of the new robotic system in performing colorectal surgical procedures.METHODS: From June 2015 to November 2016, perioperative data of the first 45 patients who underwent robotic colorectal surgery with the SenhanceTM surgical robotic system were collected and analyzed. Indications for surgery included inflammatory bowel disease, colorectal cancer, endoscopically unresectable adenomas and complicated diverticular disease.RESULTS: The median age was 57 years (18-92) and the median BMI was 24 Kg/m2 (16-30). Surgical indications were colorectal cancer (66{\%}), complicated inflammatory bowel disease (18{\%}), diverticular disease (11{\%}) and endoscopically unresectable adenoma (4.4{\%}). The median operative time was 256 minutes; the median docking time 10.7 min (range 2-25). There were 3 conversions to standard laparoscopy, and none to laparotomy. All patients operated on for malignancy (28 adenocarcinoma, 2 neuroendocrine tumors) underwent an appropriate oncological procedure. The median time to discharge was 5 days (range 3-19). The incidence of post-operative complications was 35.5{\%} (Clavien-Dindo I/II-14 patients, III-2 patients). One patient was readmitted in the postoperative period. No patient required reoperation.CONCLUSION: The results of this audit suggest that adoption of The Senhance™surgical robotic system in colorectal surgery is feasible and safe. More clinical data are needed to determine whether this approach can offer any other benefits over other minimally invasive surgical techniques. This article is protected by copyright. All rights reserved.",
keywords = "Journal Article",
author = "Antonino Spinelli and Giulia David and Stefano Gidaro and Michele Carvello and Matteo Sacchi and Marco Montorsi and Isacco Montroni",
note = "This article is protected by copyright. All rights reserved.",
year = "2017",
month = "9",
day = "14",
doi = "10.1111/codi.13882",
language = "English",
journal = "Colorectal Disease",
issn = "1462-8910",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - First experience in colorectal surgery with a new robotic platform with haptic feedback

AU - Spinelli, Antonino

AU - David, Giulia

AU - Gidaro, Stefano

AU - Carvello, Michele

AU - Sacchi, Matteo

AU - Montorsi, Marco

AU - Montroni, Isacco

N1 - This article is protected by copyright. All rights reserved.

PY - 2017/9/14

Y1 - 2017/9/14

N2 - The use of robotic techniques is increasing in colorectal surgery. Recently, the Senhance™surgical robotic system was introduced as a novel robotic platform designed to overcome some of the limits of standard laparoscopy. This study describes the initial, single center experience, evaluating feasibility and safety of the new robotic system in performing colorectal surgical procedures.METHODS: From June 2015 to November 2016, perioperative data of the first 45 patients who underwent robotic colorectal surgery with the SenhanceTM surgical robotic system were collected and analyzed. Indications for surgery included inflammatory bowel disease, colorectal cancer, endoscopically unresectable adenomas and complicated diverticular disease.RESULTS: The median age was 57 years (18-92) and the median BMI was 24 Kg/m2 (16-30). Surgical indications were colorectal cancer (66%), complicated inflammatory bowel disease (18%), diverticular disease (11%) and endoscopically unresectable adenoma (4.4%). The median operative time was 256 minutes; the median docking time 10.7 min (range 2-25). There were 3 conversions to standard laparoscopy, and none to laparotomy. All patients operated on for malignancy (28 adenocarcinoma, 2 neuroendocrine tumors) underwent an appropriate oncological procedure. The median time to discharge was 5 days (range 3-19). The incidence of post-operative complications was 35.5% (Clavien-Dindo I/II-14 patients, III-2 patients). One patient was readmitted in the postoperative period. No patient required reoperation.CONCLUSION: The results of this audit suggest that adoption of The Senhance™surgical robotic system in colorectal surgery is feasible and safe. More clinical data are needed to determine whether this approach can offer any other benefits over other minimally invasive surgical techniques. This article is protected by copyright. All rights reserved.

AB - The use of robotic techniques is increasing in colorectal surgery. Recently, the Senhance™surgical robotic system was introduced as a novel robotic platform designed to overcome some of the limits of standard laparoscopy. This study describes the initial, single center experience, evaluating feasibility and safety of the new robotic system in performing colorectal surgical procedures.METHODS: From June 2015 to November 2016, perioperative data of the first 45 patients who underwent robotic colorectal surgery with the SenhanceTM surgical robotic system were collected and analyzed. Indications for surgery included inflammatory bowel disease, colorectal cancer, endoscopically unresectable adenomas and complicated diverticular disease.RESULTS: The median age was 57 years (18-92) and the median BMI was 24 Kg/m2 (16-30). Surgical indications were colorectal cancer (66%), complicated inflammatory bowel disease (18%), diverticular disease (11%) and endoscopically unresectable adenoma (4.4%). The median operative time was 256 minutes; the median docking time 10.7 min (range 2-25). There were 3 conversions to standard laparoscopy, and none to laparotomy. All patients operated on for malignancy (28 adenocarcinoma, 2 neuroendocrine tumors) underwent an appropriate oncological procedure. The median time to discharge was 5 days (range 3-19). The incidence of post-operative complications was 35.5% (Clavien-Dindo I/II-14 patients, III-2 patients). One patient was readmitted in the postoperative period. No patient required reoperation.CONCLUSION: The results of this audit suggest that adoption of The Senhance™surgical robotic system in colorectal surgery is feasible and safe. More clinical data are needed to determine whether this approach can offer any other benefits over other minimally invasive surgical techniques. This article is protected by copyright. All rights reserved.

KW - Journal Article

U2 - 10.1111/codi.13882

DO - 10.1111/codi.13882

M3 - Article

C2 - 28905524

JO - Colorectal Disease

JF - Colorectal Disease

SN - 1462-8910

ER -